Scienza e Tecnologia
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
TEL AVIV, Israel and RALEIGH, N.C. , Aug. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029.
"Opaganib's potent activity against several single-stranded RNA viruses positions it as a potential treatment for many viral diseases, including COVID-19 and other viruses that are the origin of devastating epidemics. Ebola virus disease remains a major risk with recent recurring outbreaks. Opaganib has already demonstrated positive results from non-clinical studies in Ebola, and RedHill is committed to continuing its development as a potential treatment for this devastating disease," . "In addition, we continue to evaluate the potential development path to approval of RHB-104 for Crohn's disease."
Opaganib is also under development for COVID-19, with a 475-patient global Phase 2/3 study in patients hospitalized with severe COVID-19 with patient treatment and follow-up recently completed and top-line results upcoming. In parallel, opaganib is also being studied in Phase 2 U.S. studies in cholangiocarcinoma and prostate cancer, as well as development programs for other indications.
The MAP US randomized, double-blind, placebo-controlled first Phase 3 study with oral RHB-104 for Crohn's disease successfully met both its primary endpoint and its key secondary endpoints and presented the broad benefit of RHB-104 as an add-on therapy to standard-of-care treatments for Crohn's disease, including anti-TNFs. Future development path to approval is being explored.
RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, for opioid-induced constipation in adults , for the treatment of infection in adults , and for the treatment of travelers' diarrhea in adults . RedHill's key clinical late-stage development programs include: (i) , with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) , a first in class oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) ( ), an oral serine protease inhibitor in a U.S. Phase 2/3 study for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) , with positive results from a first Phase 3 study for Crohn's disease; (v) , with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) - , an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
Bryan Gibbs
Vice President
Finn Partners
+1 212 529 2236
bryan.gibbs@finnpartners.com
[1] Full prescribing information for Movantik (naloxegol) is available at: www.Movantik.com.
[2] Full prescribing information for Talicia (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.
[3] Full prescribing information for Aemcolo (rifamycin) is available at: www.Aemcolo.com.
Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg